南光化學製藥股份有限公司 Approved

最後更新時間 2025/08/09 , 02:34 AM
最後更新時間 2025/08/09 , 02:34 AM
負責人
Chen,Li-Xian
統一編號
69275313
成立日期
1973/08/20
資本額
NT$1,500,000,000
實收資本額
NT$1,009,884,720
股票代號
1752
電話
06-5984121
地址
No. 1001, Zhongshan Rd., Xinhua Dist., Tainan City, 712, Taiwan

董監事

姓名 職稱 持有股份 代表法人
Chen,Li-Xian Chairman 2.26%
Wang,Yu-Bei Director 2.91%
Chen,Ben-Song Director 5.42%
Lin,Zhi-Long Director 0.04%
Wang,Chao-Qin Independent Director 0.00%
Su,Er-Lang Independent Director 0.00%
Zhang,Bo-Ren Independent Director 0.00%
Wu,Huang-Yuan Independent Director 0.00%

營業項目

  • Wholesale of General Merchandise(452000)
  • 公司歷程

  • Change Capital to 1,500,000,000
    2013/04/15
  • 員工人數

    下載完整報告查看完整數據

    財務報表

    項目 2025 2024 2023
    Operating income 1,121,187 2,199,861 2,150,228
    Operating cost 700,800 1,452,068 1,394,665
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) 420,387 747,793 755,563
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net 420,387 747,793 755,563
    Operating expenses 239,122 437,572 495,652
    Other gain (loss), net - - -
    Operating profit (loss) 181,265 310,221 259,911
    Non-operating income and expenses -23,487 -7,017 -46,233
    Net profit (loss) before tax 157,778 303,204 213,678
    Income tax expense (benefits) 33,824 59,796 15,269
    Net profit (loss) of ongoing business for the current period 123,954 243,408 198,409
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period 123,954 243,408 198,409
    Other comprehensive profit (loss), net 0 3,426 -61
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period 123,954 246,834 198,348
    Net profit (loss) attributable to owners of parent company 123,954 243,408 198,409
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests - - -
    Comprehensive profit (loss) attributable to owners of parent company 123,954 246,834 198,348
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests - - -
    Basic earnings per share (yuan) 1 2 1
    項目 2025 2024 2023
    Net cash inflow (outflow) from operating activities 233,669 466,425 342,605
    Net cash inflows (outflows) from investing activities -194,219 -372,388 -329,509
    Net cash inflow (outflow) from financing activities -31,502 -170,968 -35,766
    Effect of Exchange Rate Changes on Cash and Cash Equivalents 0 -2 -55
    Increase (decrease) in cash and cash equivalents in the current period 7,948 -76,933 -22,725
    Beginning balance of cash and cash equivalents 301,542 378,475 401,200
    Ending balance of cash and cash equivalents 309,490 301,542 378,475
    項目 2025 2024 2023
    Current asset 1,472,200 1,455,987 1,537,677
    Non-current asset 2,339,156 2,356,887 2,318,492
    Total asset 3,811,356 3,812,874 3,856,169
    Current liability 1,155,684 1,142,819 1,282,690
    Non-current liability 271,339 248,094 196,376
    Total liability 1,427,023 1,390,913 1,479,066
    share capital 1,009,885 1,009,885 1,009,885
    Equity - secruity token - - -
    capital reserve 245,012 325,803 426,791
    retained earning 1,129,471 1,086,308 940,460
    Other equity -35 -35 -33
    Treasury stock - - -
    Total equity attributable to owners of parent company 2,384,333 2,421,961 2,377,103
    Equity attributable to former owner of business combination under common control - - -
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests - - -
    Total Equity 2,384,333 2,421,961 2,377,103
    Share capital awaiting retirement (unit: share) 0 0 0
    Issued shares of advance equity (unit: shares) 0 0 0
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 0 0 0
    Net asset value per share 23 23 23

    動產抵押

    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額

    選舉收入(政治獻金)

    收入名稱 收入金額
    總收入金額

    選舉支出(政治獻金)

    支出名稱 支出金額
    總支出金額

    標案拒往

    機關名稱 生效日期 截止日期

    進出口資料

    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)

    商標

  • 南光藥品生活品質藥
  • 南光藥品
  • 速可逆 Sugadex
  • 佑安鈣 Keepcar
  • 南光樂得 Lote N.K.
  • 點滴營養 Tenteki Eiyo
  • 艾薇斯提
  • 點滴營養(日文漢字)Tenteki Eiyo
  • 通舒健
  • 鑽顏皙
  • 專利

    政府標案

    標案名稱 機關名稱 決標日期 決標金額 是否得標

    裁判書查詢

  • Others
    2011, 2012, 2013, 2020
  • Pay severance pay, etc.
    2003
  • Exclude patent infringement, etc.
    2014, 2015, 2016
  • Petition for refund of security deposit
    2013
  • Infringement of patent rights related to property rights disputes, etc.
    2019, 2020, 2021, 2024
  • Others
    2012, 2015, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024
  • Payment order
    2009, 2022
  • Invalidating Judgment
    2007
  • Invention patent filing
    2016, 2017, 2019, 2020, 2022, 2023
  • Petition for disclaimer
    2021
  • Invalidating Judgment (Note)
    2017
  • Restitution of unjust enrichment
    2020
  • Exclude patent infringement, etc.
    2016, 2017, 2018, 2020
  • Petition filed for public summons
    2006, 2017
  • Petition for confidentiality preservation order
    2020, 2021
  • Infringement of patent rights related to property rights disputes
    2021
  • Infringement of patent rights related to property rights disputes, etc.
    2019, 2023, 2024
  • 勞權違規

    日期 違反法規法條 罰鍰金額

    污染源裁處

    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。